Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
BUSINESS
US FDA Accepts Relugolix for Review in Advanced Prostate Cancer
Myovant Sciences, a subsidiary of Sumitomo Dainippon Pharma, said on June 22 that the US FDA has accepted for review its new drug application (NDA) for relugolix for the treatment of men with advanced prostate cancer. The drug has been…
To read the full story
Related Article
- US Approves Myovant’s Relugolix Combo for Uterine Fibroids
May 28, 2021
- US FDA Accepts Myovant’s Relugolix Triple Combo for Review in Uterine Fibroids
August 19, 2020
- Relugolix Combo Filed in US for Uterine Fibroids
June 3, 2020
- Myovant Files Relugolix for Advanced Prostate Cancer in US
April 23, 2020
BUSINESS
- Lilly Confirms Orforglipron Diabetes Filings in US, Japan
August 7, 2026
- Takeda Snares US Approval for Orzeyful in Narcolepsy Type 1
August 7, 2026
- Meiji Pharma Drops Hiyasta Development in B-Cell NHL
August 7, 2026
- Inrebic Expands First-Line Treatment Options for Myelofibrosis: Expert
August 7, 2026
- AstraZeneca Japan Chief Says MFN Response Requires Drug Pricing Reform
August 5, 2026
Japan’s pharmaceutical policy appears to be entering a new phase. The government’s newly approved honebuto policy and growth strategy both…
A few weeks ago, I had coffee with a very talented executive. Let’s call him Kenji. He has a great job, a big salary, and a solid team. But he was unhappy. He felt bored and wanted a new challenge.…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…